Trial Profile
Vaccination in the peripheral stem cell transplant setting for multiple myeloma: the use of autologous tumor cells with an allogeneic GM-CSF producing cell line
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Oct 2005 New trial record.